ST. LOUIS, July 2, 2013 (GLOBE NEWSWIRE) -- Express Scripts Holding Company (Nasdaq:ESRX), the largest pharmacy benefit management company in North America, announced today its intention to release its second quarter earnings on Monday, July 29, 2013 after the market closes and will hold its quarterly conference call to discuss second quarter results on Tuesday, July 30, 2013, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
This call is being webcast and can be accessed at Express Scripts' web site at www.express-scripts.com/corporate
About Express ScriptsExpress Scripts (Nasdaq:ESRX) manages more than a billion prescriptions each year for tens of millions of patients. On behalf of our clients – employers, health plans, unions and government health programs – we make the use of prescription drugs safer and more affordable. Express Scripts uniquely combines three capabilities – behavioral sciences, clinical specialization and actionable data – to create Health Decision Science℠, our innovative approach to help individuals make the best drug choices, pharmacy choices and health choices. Better decisions mean healthier outcomes. Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.
CONTACT: Jeffrey Hall, Chief Financial Officer David Myers, Vice President Investor Relations (314) 810-3115 Investor.email@example.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts